PRESS RELEASES
Lilly and Avid Receive Complete Response Letter from FDA for Amyvid
Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid
Lilly Announces Completion of Avid Acquisition and FDA Priority Review for Florbetapir